Regeneron and BenevolentAI unveiled a deal and a platform, respectively, on Tuesday that could yield therapies against 2019-nCoV that go beyond anti-inflammatory drugs for other viral infections. The first nine clinical trials of medicines for...

DISEASE CATEGORY: Musculoskeletal INDICATION: Dupuytren's disease Inhibiting TNFR2 and IL-33 could treat Dupuytren's disease, which is characterized by progressive fibrosis of the palmar and digital fascia. The effector cells in Dupuytren's, the myofibroblasts, mediate the...

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...

Kite’s KTE-X19 under review in Europe   EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T...

AbCellera Biologics Inc. has started a program to discover mAbs as potential treatments for patients infected with the 2019-nCoV that was first identified in Wuhan, China, the company’s CEO, Carl Hansen, told BioCentury. The work...

Public release of the genetic sequence of the coronavirus first detected in Wuhan, China acted as a starter pistol, setting off a race to develop medical countermeasures. Beyond the potential for containing and hopefully eradicating...

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give...

The rapid sharing of the genetic sequence of the 2019 novel coronavirus (2019-nCoV), first identified in Wuhan, China, has sparked an extraordinary response from biopharma companies, academic researchers and governments. At least seven initiatives to...

Deerfield forms Orchard Innovations in Yeda collaboration on translation  Deerfield Management Co. launched Orchard Innovations LLC to pursue translational R&D derived from Weizmann Institute of Science research. Yeda Research and Development Co. Ltd., Weizmann’s commercial...